Barclays downgraded Reata Pharmaceuticals (RETA) to Equal Weight from Overweight with a price target of $172, up from $110. The analyst cites the announced acquisition by Biogen (BIIB) for the downgrade.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RETA:
- Biotech Alert: Searches spiking for these stocks today
- Reata Pharmaceuticals price target raised to $173 from $85 at Baird
- Reata Pharmaceuticals downgraded to Neutral from Buy at Ladenburg
- Reata downgraded to Market Perform from Outperform at SVB Securities
- Reata Pharmaceuticals downgraded to Hold from Buy at Jefferies
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue